Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Myasthenia Gravis, Generalized

In brief

This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.

Key facts

Study ID

NCT07596901

Run by

Aurinia Pharmaceuticals Inc.

People needed

81

Starts

2026-04-22

Expected to finish

2029-03-02

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Aurinia Investigational Site — Pasadena, California, United States (enrolling)
• Aurinia Investigational Site — Altamonte Springs, Florida, United States (enrolling)
• Aurinia Investigational Site — Boca Raton, Florida, United States (enrolling)
• Aurinia Investigational Site — Homestead, Florida, United States (enrolling)
• Aurinia Investigational Site — Miami, Florida, United States (enrolling)
• Aurinia Investigational Site — Miami, Florida, United States (enrolling)
• Aurinia Investigational Site — Chicago, Illinois, United States (enrolling)
• Aurinia Investigational Site — O'Fallon, Illinois, United States (enrolling)
• Aurinia Investigational Site — Dearborn, Michigan, United States (enrolling)
• Aurinia Investigational Site — Flint, Michigan, United States (enrolling)
• Aurinia Investigational Site — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.